WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion42 on April 1-4, 2025 in Las Vegas, NV in Booth #112.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced that it has been certified as a Great Place to Work for the third year in a row.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the fourth quarter and full-year ended December 31, 2024 on Thursday, March 20, 2025.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical is the leading supplier of liquid bicarbonate in the United States.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Jesse Neri has been instrumental in strengthening Rockwell Medical's financial infrastructure and developing a stronger financial organization.
Rockwell Medical, Inc. (NASDAQ:RMTI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Heather Hunter - Senior Vice President & Chief Corporate Affairs Officer Mark Strobeck - President & Chief Executive Officer Jesse Neri - Senior Vice President of Finance Conference Call Participants Anthony Venditti - Maxim Group Operator Good morning and welcome to Rockwell Medical's Third Quarter 2024 Results Conference Call and Webcast. Please note, this event is being recorded.
Rockwell Medical (RMTI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.07 per share a year ago.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced financial and operational results for the three and nine months ended September 30, 2024.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--UPDATED Q3'24 EARNINGS DATE: Rockwell Medical will release its third quarter 2024 financial and operational results on November 12, 2024.
Rockwell Medical expects its Q3 results to gain from a high rate of customer conversions toward it compared with its primary competitor.